Dual Antithrombotic Therapy for Atrial Fibrillation and Coronary Stent Patients

Introduction to Dual Therapy

The American College of Cardiology recommends dual therapy with apixaban (Eliquis) and clopidogrel (Plavix) for patients with atrial fibrillation and a recent coronary stent, as this regimen reduces bleeding risk by approximately 50% compared to triple therapy while maintaining equivalent protection against ischemic events 1, 2

The American College of Cardiology suggests stopping aspirin immediately after hospital discharge and continuing only Eliquis plus Plavix, with brief triple therapy (Eliquis + aspirin + Plavix) used only during the immediate peri-PCI hospitalization period, with a maximum duration of 1 week for most patients 1, 2
Triple therapy can extend up to 1 month only in highly selected patients at exceptionally high thrombotic risk and low bleeding risk, as recommended by the European Heart Journal 3, 1

For patients with acute coronary syndrome (ACS), the American College of Cardiology recommends continuing Eliquis + Plavix for 6-12 months post-PCI, and after 12 months, discontinuing Plavix and continuing Eliquis alone indefinitely 4, 1
For patients with stable coronary disease, the American College of Cardiology suggests continuing Eliquis + Plavix for 6 months post-PCI, and after 6 months, discontinuing Plavix and continuing Eliquis alone indefinitely 1

The American College of Cardiology cites the AUGUSTUS trial, which demonstrated that aspirin doubled total bleeding events without reducing ischemic events when added to apixaban plus a P2Y12 inhibitor, although the specific details of the trial are not provided in this context 1
The PIONEER AF-PCI trial showed that rivaroxaban + P2Y12 inhibitor reduced bleeding by 41% vs. triple therapy, as reported by the American College of Cardiology 1
The RE-DUAL PCI trial demonstrated that dabigatran + P2Y12 inhibitor reduced bleeding by 48% vs. triple therapy, according to the American College of Cardiology 1

The American College of Cardiology recommends using clopidogrel (Plavix) as the P2Y12 inhibitor, not prasugrel or ticagrelor, as the more potent agents substantially increase bleeding risk when combined with anticoagulation 1, 2
The American College of Cardiology suggests using apixaban (Eliquis) at standard dosing (5 mg twice daily) unless dose-reduction criteria are met, and notes that DOACs like Eliquis are strongly preferred over warfarin due to 50% lower intracranial hemorrhage risk 1, 2

The American College of Cardiology recommends implementing measures for all patients on dual antithrombotic therapy, including prescribing proton pump inhibitors for gastrointestinal protection, optimizing blood pressure control, avoiding NSAIDs, and monitoring renal function 2, 5

The European Heart Journal and the American College of Cardiology advise against continuing triple therapy beyond 1 month, as this is the single most common error leading to preventable major bleeding, and also recommend against adding antiplatelet therapy to anticoagulation for stroke prevention alone, and against using prasugrel or ticagrelor in combination with anticoagulation unless absolutely necessary 2, 3, 1

The American College of Cardiology recommends that patients with atrial fibrillation and recent acute coronary syndrome or percutaneous coronary intervention (PCI) be treated with dual therapy consisting of apixaban and clopidogrel, without aspirin, to reduce bleeding risk by approximately 50% while maintaining equivalent protection against ischemic events 6

For patients with stable coronary disease or prior myocardial infarction/stroke more than 12 months ago, anticoagulation alone with apixaban is sufficient, and all antiplatelet therapy should be stopped 6
The European Heart Journal suggests that proton pump inhibitors be used for gastrointestinal protection in patients on dual antithrombotic therapy 7, 8
Blood pressure optimization to target less than 130/80 mmHg is recommended to reduce bleeding risk, as suggested by the European Heart Journal 9

The American College of Cardiology guidelines recommend that patients on dual antithrombotic therapy require protective measures, including proton pump inhibitors and blood pressure optimization, to mitigate bleeding risk 6
The European Heart Journal recommends that patients with renal impairment require dose adjustment of apixaban, and that renal function be monitored regularly 9

For patients with contrast-induced nephropathy, the American College of Cardiology recommends monitoring creatinine levels 48-72 hours post-procedure, adjusting apixaban dose if necessary, and ensuring adequate hydration 6
Hematology consultation is recommended if a patient experiences recurrent bleeding despite appropriate therapy, as suggested by the European Heart Journal 7
Nephrology consultation is recommended if creatinine clearance is less than 30 mL/min, requiring dose adjustment decisions, as suggested by the European Heart Journal 9